PT  - JOURNAL ARTICLE
AU  - Zhou, Yangyang
AU  - Li, Wenqiang
AU  - Zhang, Hongqi
AU  - Luo, Bin
AU  - Wang, Yang
AU  - Wang, Jun
AU  - Zhang, Pinyuan
AU  - Li, Liang
AU  - Xiao, Fushun
AU  - Mu, Shiqing
AU  - Liu, Jian
AU  - Zhao, Yuanli
AU  - Yang, Xinjian
AU  - Jiang, Peng
TI  - Guided versus standard antiplatelet therapy in patients undergoing interventional intracranial aneurysm treatment using stents: protocol of a cluster randomized controlled cohort study
AID  - 10.1101/2023.11.16.23298664
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.16.23298664
4099  - http://medrxiv.org/content/early/2023/11/17/2023.11.16.23298664.short
4100  - http://medrxiv.org/content/early/2023/11/17/2023.11.16.23298664.full
AB  - Background The goal of standard dual antiplatelet therapy (SDAT) in patients undergoing endovascular interventional treatment of intracranial aneurysms is to prevent thrombosis; however, some patients have a poor response to these drugs, which increases the risk of cerebral infarction. This study aims to examine whether adjusting antiplatelet therapy based on light transmission aggregometry (LTA) can reduce the incidence of ischemic events compared with SDAT.Methods We will conduct a cluster randomized controlled trial using 16 treatment teams from eight hospitals in mainland China, enrolling 590 patients with unruptured intracranial aneurysms treated using endovascular stent placement. The treatment teams serving as clusters will be randomly assigned to either the test or control group at a 1:1 ratio. Test group patients will receive an antiplatelet regimen guided by LTA. Control group patients will receive SDAT. Patients will be followed for 1 month after the treatment period. The primary outcome measure is cerebral ischemic events within 30 days of stent placement, including stent thrombosis, ischemic stroke, and transient ischemic attack. The safety measure is all bleeding events within 30 days of treatment.Discussion The trial aims to determine whether LTA-guided antiplatelet therapy reduces the incidence of ischemic events without increasing the risk of bleeding in patients with intracranial aneurysms treated with endovascular stenting. Completion of this clinical trial may provide an individualized safe and effective regimen for antiplatelet therapy.Trial registration ClinicalTrials.gov, NCT05825391. Registered on April 11, 2023.What is already known on this topic Dual antiplatelet therapy is administered to reduce thrombotic events in neurointerventional therapy of intracranial aneurysms. Platelet function testing is used to evaluate the antiplatelet effect of aspirin and clopidogrel.What this study adds The trial aims to determine whether LTA-guided antiplatelet therapy reduces the incidence of ischemic events without increasing the risk of bleeding in patients with intracranial aneurysms treated with endovascular stenting.How this study might affect research, practice or policy For stent neurointerventional therapy of unruptured intracranial aneurysms, this study could provide a promising method for adjusting appropriate antiplatelet therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05825391Funding StatementThis study was sponsored by the National Natural Science Foundation of China (grant numbers: 81671139, 82072036, 82372058 and 82371315), Capital Funds for Health Improvement and Research (grant numbers:2022-1-2041) and Summit Talent Program (grant numbers: DFL20220504).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves human participants and was approved by the Ethics Committee of Beijing Tiantan Hospital (KY2022-068-02).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors